重大事件
外國發行人報告
6-K
2026-06-25
Cellectis股東周年大會通過29項決議案 第30項被否決
AI 繁中摘要
Cellectis（納斯達克：CLLS；Euronext Growth：ALCLS）於2026年6月25日召開股東周年大會，會上約55.84%投票權獲行使。根據董事會建議，第1至29項決議案獲通過，第30項決議案被否決。詳細投票結果已上載至公司網站。是次會議為例行股東大會，未涉及重大業務變動或財務數據披露，對投資者的直接影響有限，但反映股東對管理層策略的普遍支持。
展開英文正文
EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFilingEXHIBIT 99.1 Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026 NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today its shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. At the meeting, during which approximately 55,84% of voting rights were exercised, resolutions 1 through 29 were adopted, while resolution 30 was rejected, consistent with the recommendations of the board of directors. The detailed results of the vote and the resolutions are available on Cellectis’ website:https://www.cellectis.com/en/investors/general-meetings/ About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish. Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X. For further information on Cellectis, please contact: Media contacts:Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, [email protected] Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Relations contact: Arthur Stril, Chief Financial Officer & Chief Business Officer, [email protected] Attachments Cellectis GM June 25, 2026 - PR voting results.pdf (https://ml.globenewswire.com/Resource/Download/77b3bdf8-2bfd-4c13-8c55-6d237556aa0d)